{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:52:10Z","timestamp":1792266730107,"version":"4.4.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jdcr.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:51:07Z","timestamp":1783529467000},"page":"159-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Introduction to virtual special issue on glucagon-like peptide-1 agonists and the skin"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5072-0423","authenticated-orcid":false,"given":"Nikki A.","family":"Levin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2026.07.005_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/diseases13050127","article-title":"A closer look at the dermatological profile of GLP-1 agonists","volume":"13","author":"Persson","year":"2025","journal-title":"Diseases"},{"issue":"5","key":"10.1016\/j.jdcr.2026.07.005_bib2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000544023","article-title":"Dermatologic implications of glucagon-like peptide-1 receptor agonist medications","volume":"11","author":"Burke","year":"2025","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.jdcr.2026.07.005_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s40257-026-01049-8","article-title":"A systematic review of the clinical impact of GLP-1 receptor agonists in hidradenitis suppurativa","author":"Visan","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jdcr.2026.07.005_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jdcr.2026.03.015","article-title":"Rapid remission of Hailey-Hailey disease with tirzepatide therapy: a case report","volume":"71","author":"Velusamy","year":"2026","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2026.07.005_bib5","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jdcr.2026.03.061","article-title":"Remission of erythromelalgia after semaglutide initiation: a case report","volume":"72","author":"Laugsand","year":"2026","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2026.07.005_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdcr.2026.06.006","article-title":"Case report: tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use","author":"Peng","year":"2026","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2026.07.005_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jdcr.2026.03.062","article-title":"Photodistributed exfoliative dermatitis associated with semaglutide: expanding the spectrum of glucagon-like peptide-1 receptor agonist-associated cutaneous reactions","volume":"72","author":"Kann","year":"2026","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2026.07.005_bib8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jdcr.2026.03.033","article-title":"Symmetrical drug-related intertriginous and flexural exanthema associated with tirzepatide","volume":"71","author":"Goodman","year":"2026","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2026.07.005_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdcr.2026.02.034","article-title":"Not all \u201cnatural\u201d is safe: a naturally occurring glucagon-like peptide-1 mimetic associated with drug-induced hypersensitivity syndrome","volume":"71","author":"Xu","year":"2026","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2026.07.005_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdcr.2026.03.042","article-title":"Facial nodules following filler injections after initiating compounded tirzepatide use","volume":"72","author":"Moore","year":"2026","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jdcr.2026.07.005_bib12","doi-asserted-by":"crossref","unstructured":"Howard T., Clichy-Silva A., Kerdel F. Papular granuloma annuare associated with tirzepatide: a case report. JAAD Case Rep. 2026; 74:225-227.","DOI":"10.1016\/j.jdcr.2026.06.046"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626004170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:39:21Z","timestamp":1792265961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626004170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":11,"alternative-id":["S2352512626004170"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.07.005","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Introduction to virtual special issue on glucagon-like peptide-1 agonists and the skin","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}